Click here to return to the Reference Table

Category: Hematopoietic Malignancies
Cancer type: Multiple Myeloma
Descriptor: Poor Prognosis

Reference Number: 163
Seidel, C., Borset, M., Hjorth-Hansen, H., Sundan, A. & Waage, A. Role of hepatocyte growth factor and its receptor c-met in multiple myeloma. Med Oncol 15, 145-53 (1998).
PubMed link      E-mail link

Reference Number: 164
Seidel, C. et al. Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy. Br J Haematol 119, 672-6 (2002).
PubMed link      E-mail link

Reference Number: 165
Turesson, I. et al. Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors. Br J Haematol 106, 1005-12 (1999).
PubMed link      E-mail link

Reference Number: 515
Kara IO, Sahin B, Gunesacar R, Unsal C. Clinical significance of hepatocyte growth factor, platelet-derived growth factor-AB, and transforming growth factor-alpha in bone marrow and peripheral blood of patients with multiple myeloma. Adv Ther. 23, 635-45 (2006)
PubMed link      E-mail link

Reference Number: 809
Ludek P, Hana S, Zdenek A, Martina A, Dana K, Tomas B, Lucie K, Marta K, Jaroslav M, Miroslav P, Jiri V, Roman H. Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration. Eur J Haematol. 84, 332-6 (2010)
PubMed link      E-mail link

Reference Number: 810
Pour L, Svachova H, Adam Z, Mikulkova Z, Buresova L, Kovarova L, Buchler T, Penka M, Vorlicek J, Hajek R. Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma. Neoplasma. 57, 29-34 (2010)
PubMed link      E-mail link